Pancreatic Carcinoma

Overview & Definition^[1]

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive epithelial malignancy arising from the exocrine pancreatic ducts (the small intercalated and intralobular ducts that line the glandular parenchyma). It is the fourth leading cause of cancer death in the United States and most developed countries (after lung, colorectal, and breast/prostate) and has the worst 5-year survival of any major malignancy — approximately 10% overall, a figure that has barely budged in four decades despite extraordinary efforts in surgery, chemotherapy, radiation, targeted therapy, and immunotherapy.^[1][2][5]

Approximately 70% arise in the head of the pancreas, 20% in the body, and 10% in the tail. Head tumours present earlier because they obstruct the intrapancreatic common bile duct and produce painless obstructive jaundice. Body and tail tumours are clinically silent until they invade the retroperitoneal coeliac/superior mesenteric plexus (causing back pain) or metastasise to liver or peritoneum, at which point they are almost never resectable.^[2][5]

The clinical challenge is early detection. There is no effective screening test for the general population; symptoms are non-specific until biliary obstruction or back pain develop; the pancreas is retroperitoneal and hidden from palpation; and tumour biology is uniquely aggressive, with rapid local invasion, perineural spread, early lymphatic and haematogenous dissemination, and a dense desmoplastic stroma that excludes chemotherapy and immune cells. The result is that over 80% of patients present at an advanced, unresectable stage, and even those who reach the operating table often recur within 24 months.^[1][6]

PDAC must be distinguished from a wider family of pancreatic neoplasms. The pancreatic ductal adenocarcinoma is the dominant lesion (over 90% of all pancreatic malignancies), but the same anatomical region gives rise to ampullary carcinoma, cholangiocarcinoma of the distal bile duct, pancreatic neuroendocrine tumours (pNETs), cystic neoplasms (IPMN, MCN, serous cystadenoma, solid pseudopapillary), acinar cell carcinoma, and the rare pancreatoblastoma. Each has its own biology, staging system, and treatment pathway; the focus of this chapter is pancreatic ductal adenocarcinoma, with periampullary and pNET touched on where they are the commonest source of confusion at the bedside and in the exam hall.^[2][5]

Classification^[1]

By anatomical site (determines presentation and operability)^[1]

The anatomical location of a PDAC within the gland dictates both how it presents and whether it is resectable:^[2][5]

• Head of pancreas (60 to 70%) — the commonest location. The head sits within the C-loop of the duodenum and contains the intrapancreatic distal common bile duct and the main pancreatic duct (duct of Wirsung) as it joins the ampulla of Vater. A tumour in this region compresses the distal CBD early, producing painless obstructive jaundice (the textbook presentation), and may also obstruct the duodenum (gastric outlet obstruction late in the disease). Head tumours present earlier than body/tail tumours and have a higher resection rate (around 20 to 25%) because symptoms develop before distant spread.^[2]
• Uncinate process — the inferior/medial hook of the pancreatic head. Uncinate tumours characteristically invade the superior mesenteric vein (SMV)/portal vein (PV) axis and the superior mesenteric artery (SMA), and they often present with duodenal obstruction rather than jaundice (because the uncinate lies inferior to the CBD). Uncinate tumours have a higher R1 margin rate and a worse prognosis than other head tumours.^[5]
• Body (15 to 20%) — sits anterior to the SMA, coeliac axis, and aorta. Body tumours are clinically silent until they invade the coeliac plexus and the superior mesenteric plexus, producing the characteristic epigastric pain radiating through to the back, worse at night, partially relieved by leaning forward. By the time this pain develops, vascular encasement is usually present and resection is rarely possible.^[2]
• Tail (5 to 10%) — the most lateral portion, abutting the splenic hilum. Tail tumours present even later than body tumours, often with left upper quadrant pain, splenomegaly, splenic-vein thrombosis with isolated gastric varices (sinistral/left-sided portal hypertension), and early haematogenous metastases to the liver and peritoneum. Almost never resectable at diagnosis.^[5]
• Diffuse/multifocal (5 to 10%) — extensive glandular involvement at diagnosis. Behaviour is that of an advanced, unresectable lesion.^[2]

By resectability (the most important clinical classification — drives treatment)^[1]

This four-tier NCCN/AHPBA/SSO consensus classification is the cornerstone of treatment selection and is now the standard for MDT discussion, trial entry, and exam answers:^[1][5][4]

Periampullary carcinoma^[1]

Periampullary carcinoma is an umbrella term for tumours arising from the ampulla of Vater, the intrapancreatic distal common bile duct, or the second part of the duodenum (not the pancreas itself). They are grouped with pancreatic head cancer because they present in the same way — progressive painless jaundice — and are treated with the same operation (pancreatoduodenectomy). However, periampullary tumours have a substantially better prognosis than PDAC (5-year survival 40 to 50% after Whipple vs 20 to 25% for PDAC), partly because they are biologically less aggressive and partly because they declare themselves with jaundice while still small. The differential within the periampullary group is:^[2][5]

• Ampullary adenocarcinoma (true ampullary, intestinal type) — best prognosis; 5-year survival 50 to 70% after Whipple.
• Distal cholangiocarcinoma (intrapancreatic CBD) — intermediate prognosis; 5-year survival 30 to 40%.
• Duodenal adenocarcinoma — 5-year survival 40 to 50%.
• PDAC of the head — worst; 5-year survival 20 to 25% (with modern adjuvant FOLFIRINOX).^[2]

Histological variants of pancreatic cancer^[1]

Although "pancreatic cancer" is shorthand for PDAC, the differential is worth knowing:^[2][5]

• Ductal adenocarcinoma (PDAC) — over 90% of pancreatic malignancies. Driven by KRAS (over 90%), TP53 (50 to 75%), CDKN2A/p16 (over 90%), SMAD4/DPC4 (about 55%). Arises from pancreatic intraepithelial neoplasia (PanIN) precursor lesions.
• Pancreatic neuroendocrine tumour (pNET) — 3 to 5% of pancreatic neoplasms. Subdivided into functional (insulinoma, gastrinoma/Zollinger-Ellison, glucagonoma, VIPoma, somatostatinoma) and non-functional. Slower growing, hypervascular on CT (a useful discriminator), better prognosis (5-year survival 50 to 60% for localised disease). Associated with MEN1 and von Hippel-Lindau syndromes.
• Acinar cell carcinoma — rare; presents with the Schmid triad of subcutaneous fat necrosis, polyarthralgia, and eosinophilia from lipase hypersecretion.
• Mucinous cystic neoplasm (MCN) — almost exclusively in women in their 40s, body/tail, ovarian-type stroma, premalignant.
• Intraductal papillary mucinous neoplasm (IPMN) — mucin-producing cystic tumour of the pancreatic duct. Main-duct IPMN has a 40 to 70% lifetime risk of malignancy (resect); branch-duct IPMN is lower risk (observe unless cyst >3 cm, mural nodule, or main pancreatic duct dilated >5 mm — the Fukuoka/Kyoto criteria).
• Solid pseudopapillary neoplasm — young women; low-grade malignant; excellent prognosis after resection.
• Serous cystadenoma — benign; "honeycomb" microcystic appearance; observe unless symptomatic.
• Pancreatoblastoma — paediatric tumour; responds to chemotherapy.
• Secondary tumours — renal cell carcinoma, breast, lung, melanoma; rare; usually multifocal.^[1][5]

Enlarge

Epidemiology & Risk Factors^[1]

Burden of disease^[1]

Pancreatic cancer sits in the unenviable position of being the twelfth most common cancer globally but the fourth leading cause of cancer death (after lung, colorectal, and breast/prostate in most registries) — incidence and mortality are almost equal because the disease is so lethal.^[1][2][13] In 2020, the GLOBOCAN estimate was 495,773 new cases and 466,003 deaths worldwide. In the United States, 64,050 new cases and 50,550 deaths were projected for 2023, making PDAC the 4th cause of cancer death. By 2030, PDAC is projected to become the 2nd leading cause of cancer death in the United States (surpassing colorectal and breast/prostate) on current incidence trends. The median age at diagnosis is 70 years; the male:female ratio is approximately 1.3:1; and incidence is highest in populations of European ancestry and lowest in those of African or Asian ancestry within multi-ethnic countries.^[13][1]

Non-modifiable risk factors^[1]

• Older age — peak incidence in the 7th to 8th decade; rare under 40; over 90% of cases occur in those over 55.
• Male sex — modest 1.3:1 male predominance.
• Non-O blood group — modestly increased risk (A, B, AB), possibly because of cross-reactivity with bacterial surface antigens.
• Family history — present in 5 to 10% of patients. A single first-degree relative confers a 2-fold increased risk; two or more first-degree relatives confer a 6 to 10-fold increased risk ("familial pancreatic cancer", defined by the consensus criteria as ≥2 first-degree relatives with PDAC, none of whom carry an identifiable germline mutation).^[3][14]
• Inherited cancer syndromes — a major focus of the modern high-risk clinic.^[3][14][2]
  • BRCA2 mutation (and to a lesser extent BRCA1) — confers a 3 to 10-fold lifetime risk of pancreatic cancer (cumulative risk 5 to 10%). Same gene implicated in hereditary breast and ovarian cancer. PARP inhibitors (olaparib) are the matched targeted therapy in metastatic disease.
  • PALB2 — partner and localiser of BRCA2; lifetime pancreatic cancer risk ~5%.
  • ATM — heterozygous ATM carriers have a 2 to 3-fold increased risk.
  • Peutz-Jeghers syndrome (STK11/LKB1) — mucocutaneous pigmentation, hamartomatous GI polyps, and a cumulative lifetime pancreatic cancer risk of 11 to 36% (the highest of any hereditary syndrome for PDAC). Surveillance recommended from age 30 to 35.
  • Lynch syndrome (mismatch-repair mutations MLH1, MSH2, MSH6, PMS2) — modest 4 to 8-fold increased pancreatic cancer risk; MSI-H/dMMR tumours respond to pembrolizumab.
  • Familial atypical multiple mole melanoma (FAMMM) syndrome, CDKN2A mutation — lifetime pancreatic cancer risk 15 to 20% in carriers.
  • Hereditary pancreatitis (PRSS1, SPINK1 mutations) — chronic pancreatitis from childhood, with a cumulative lifetime pancreatic cancer risk of 40 to 55%, predominantly in the second half of life. The combination of chronic inflammation and a germline cancer-predisposition mutation is uniquely carcinogenic.
  • Von Hippel-Lindau — serous cystadenomas, pNETs; modest PDAC risk.
  • MEN1 — pNETs (gastrinoma, insulinoma), not classical PDAC.
  • Li-Fraumeni (TP53) — modestly increased PDAC risk; many other cancers.
  • Cystic fibrosis — modestly increased PDAC risk.

Modifiable risk factors^[1]

• Smoking — the most important modifiable risk factor. In a meta-analysis of 82 studies, current smokers had a 75% increased risk of pancreatic cancer (relative risk 1.74 vs never-smokers; former smokers 1.2), the risk remaining elevated for a minimum of 10 years after cessation; at a population smoking prevalence of 30%, the population attributable risk is about 20%.^[13][15]
• Chronic pancreatitis — a recognised risk factor on the generic risk-factor lists, particularly long-standing and hereditary disease.^[2][5]
• Diabetes mellitus — long-standing diabetes is a recognised risk factor; conversely, new-onset diabetes in an older patient with weight loss may be a presenting feature of pancreatic cancer and warrants investigation.^[2][3]
• Obesity — a recognised risk factor in observational data.^[2][13]
• Alcohol — heavy alcohol intake is linked to pancreatic cancer, largely through the intermediate step of chronic pancreatitis.^[2]
• Diet — diets high in red and processed meat are associated with higher risk, and fruit- and vegetable-rich diets with lower risk, in observational data.^[3]
• Occupational exposures and chronic infection — recognised but small contributors to the overall burden.^[13]
• Chronic H. pylori infection, hepatitis B, and periodontal disease have all been linked in observational data; the effect sizes are modest and the mechanisms uncertain.

Pathophysiology^[1]

The PanIN-to-carcinoma sequence^[1]

PDAC develops from a stepwise accumulation of genetic and epigenetic changes in the ductal epithelium. The dominant precursor lesion is pancreatic intraepithelial neoplasia (PanIN) — a microscopic, non-invasive lesion graded PanIN-1A, PanIN-1B, PanIN-2, and PanIN-3 (carcinoma in situ). PanIN-1A lesions are flat epithelial lesions with mild atypia; PanIN-1B are papillary without atypia; PanIN-2 show flat or papillary architecture with moderate atypia; PanIN-3 show marked atypia and cribriform architecture, with an intact basement membrane. Most PanIN lesions are clinically silent and are detected incidentally in resected specimens or at autopsy. The progression from low-grade PanIN to invasive PDAC takes 10 to 20 years on average — a window of opportunity for early detection that is, as yet, unrealised at the population level.^[1][5][6]

The genetic cascade parallels the histological progression:^[5][2][1]

1. KRAS mutation — an activating point mutation in KRAS is the commonest driver event in PDAC and one of the earliest events in pancreatic tumorigenesis, already present in low-grade precursor (PanIN) lesions. The mutation locks KRAS in its GTP-bound active state, driving constitutive RAS/MAPK and PI3K signalling.^[5]
2. CDKN2A (p16) inactivation — like KRAS, an early event in pancreatic tumorigenesis. CDKN2A encodes the p16 cell-cycle checkpoint, and its loss removes a critical brake on the G1/S transition.^[5]
3. TP53 mutation — one of the four major driver genes. Loss of p53 removes the DNA-damage response, allowing accumulation of further mutations and genomic instability.^[5]
4. SMAD4 (DPC4) loss — one of the four major driver genes. SMAD4 is a downstream effector of TGF-beta signalling; its loss abolishes TGF-beta-mediated growth inhibition.^[5]

The roughly 5 to 10% of PDACs that are KRAS-wild-type are enriched for actionable alterations — BRCA1/2, PALB2, ATM, mismatch-repair deficiency (MSI-H), NRG1, ALK, NTRK, BRAF — and are the primary beneficiaries of next-generation sequencing and matched targeted therapy.^[5]

The desmoplastic stroma^[1]

A defining histological feature of PDAC is the dense desmoplastic stroma that surrounds the malignant ducts. The stroma is produced by pancreatic stellate cells activated by tumour-derived TGF-beta, PDGF, and sonic hedgehog; it contains dense collagen, fibronectin, and hyaluronic acid, and is populated by myofibroblasts, suppressive immune cells (M2 macrophages, myeloid-derived suppressor cells, regulatory T cells), and a sparse microvasculature.^[5][1]

The stroma has three major consequences for tumour biology:^[5][1]

1. Hypovascularity — the stroma compresses intratumoural vessels, producing a hypoxic, nutrient-poor microenvironment. This explains why PDAC is hypoenhancing on arterial-phase CT (the radiologist's sign) and is poorly penetrated by systemic chemotherapy.
2. Chemoresistance — the high interstitial pressure and physical barrier exclude drug molecules from the tumour parenchyma. Even when drug reaches the stroma, the hypoxic environment selects for quiescent, drug-resistant clones.
3. Immune exclusion — the stroma is profoundly immunosuppressive; checkpoint inhibitors (anti-PD-1, anti-CTLA-4) have shown essentially no activity in microsatellite-stable PDAC (response rates <5%) outside the rare MSI-H subset.^[1]

Stromal depletion (PEGPH20, sonic-hedgehog inhibitors) has so far failed in randomised trials — paradoxically, aggressive stromal depletion in some models accelerated disease — and the field has moved on to combination immunotherapy and KRAS-targeted therapy.^[5]

Molecular subtypes^[1]

Bulk and single-cell transcriptomic studies (Bailey 2016, Moffitt 2015) have defined two main molecular subtypes of PDAC:^[5][1]

• Classical / pancreatic progenitor — expresses adhesion and epithelial genes (GATA6, PDX1); better prognosis; more responsive to 5-FU-based chemotherapy.
• Basal-like / squamous — expresses mesenchymal and inflammatory genes (TP63, S100A2); worse prognosis; more chemoresistant; the dominant subtype in SMAD4-mutated tumours.^[5]

A clinically useful genomic classification (Waddell 2015, ICGC whole-genome sequencing) divides PDAC into four structural variants: stable (≤50 structural variants, often aneuploid, KRAS wild-type enriched), locally rearranged (focal events on one or two chromosomes, BRCA-mutated enriched), scattered (moderate number of events, the largest group), and unstable (>200 events, BRCA/PALB2/DNA-repair mutated). The unstable and locally rearranged subtypes are the targets of platinum-based chemotherapy and PARP inhibitors.^[5]

Spread^[1]

PDAC disseminates by four principal routes:^[1][2][5]

• Direct invasion — duodenum, distal stomach, common bile duct, portal vein, splenic vein, superior mesenteric vessels, and the coeliac and superior mesenteric plexuses (producing the characteristic back pain that is often the first symptom of body/tail tumours).
• Lymphatic — to peripancreatic, coeliac, superior mesenteric, para-aortic, and mediastinal nodes. Nodal involvement is present in over 70% of resected specimens and is the most powerful adverse prognostic factor after margin status.
• Haematogenous — to the liver (most common, via portal venous drainage), lungs, bone, and brain. The liver is the dominant first site of distant metastasis.
• Peritoneal — carcinomatosis and malignant ascites; common with tail tumours and after surgical violation of the tumour capsule.
• Perineural — the desmoplastic stroma tracks along the retroperitoneal nerve sheaths, a route considered characteristic of PDAC and the anatomical basis for the intractable back pain that dominates advanced disease.^[1]

Enlarge

Clinical Presentation^[1]

Head of pancreas (the classic presentation)^[1]

Painless obstructive jaundice is the textbook entry point. A tumour in the pancreatic head compresses the intrapancreatic distal common bile duct, and the obstructed bile regurgitates into the systemic circulation. The result is:^[2][1]

• Progressive yellowing of skin and sclera — the patient or family notices yellow eyes first, then a sallow complexion. The jaundice is painless (distinguishing it from the painful jaundice of biliary colic and choledocholithiasis) and progressive (worsens over weeks).
• Dark urine (bilirubinuria) — conjugated bilirubin is water-soluble and excreted in the urine; this is often the first symptom, predating scleral icterus by days.
• Pale/clay-coloured (acholic) stools — the absence of stercobilin in the gut produces putty-coloured, smelly, floating stools (steatorrhoea may coexist from pancreatic exocrine insufficiency).
• Pruritus — bile salt deposition in the skin produces intense, generalised itching, often worse at night; excoriations are visible on examination.
• Weight loss — often marked (over 10% of body weight) and rapid (over months), driven by anorexia, early satiety, malabsorption, and the catabolic state of cancer cachexia.
• Anorexia and fatigue — non-specific but almost universal.
• Dull epigastric pain — may be present but is not the dominant feature; pain is more typical of body/tail tumours.^[2]

The combination of painless jaundice + weight loss + palpable non-tender gallbladder (Courvoisier's sign) is the diagnostic triad that should trigger urgent cross-sectional imaging within 24 to 48 hours. In real practice, however, the gallbladder is palpable in only 20 to 30% of head-tumour patients — the absence of a palpable gallbladder does not exclude cancer.^[1][2]

Body and tail^[1]

Body and tail tumours lack the early-warning biliary obstruction of head tumours, so they declare themselves only when they invade the retroperitoneum or metastasise. The classic picture is:^[2][5]

• Severe epigastric pain radiating through to the back — gnawing, constant, often worse at night, and partially relieved by leaning forward (the patient may be seen hunched over a chair). The pain is mediated by invasion of the coeliac and superior mesenteric plexuses and is one of the most treatment-resistant cancer pain syndromes known.
• Weight loss and anorexia — the same cachexia syndrome as head tumours, often more severe because diagnosis is delayed.
• Palpable epigastric mass — late; usually represents the tumour or a metastatic liver.
• Splenomegaly, gastric varices, isolated gastric variceal haemorrhage — from splenic-vein occlusion by tail tumours (sinistral/left-sided portal hypertension). This is rare but classic; a patient with bleeding gastric varices and a normal liver should be assumed to have a tail-of-pancreas tumour until proven otherwise.
• Hepatomegaly and ascites — from liver metastases and peritoneal carcinomatosis.^[2]

Paraneoplastic and associated features (the exam pearls)^[1]

A handful of paraneoplastic phenomena are so characteristic of PDAC that they earn their own line in a viva answer:^[1][3][2]

• New-onset diabetes — the bidirectional relationship between PDAC and diabetes makes new-onset diabetes in an older, thin, weight-losing patient a paraneoplastic marker. Up to 1% of patients over 50 with new diabetes will be diagnosed with PDAC within 3 years. The mechanism is tumour-derived factors (adrenomedullin, islet amyloid polypeptide) that produce insulin resistance and beta-cell dysfunction, and the diabetes often resolves after tumour resection. New-onset diabetes in this context is now a recognised indication for cross-sectional imaging.^[1][3]
• Trousseau syndrome (migratory thrombophlebitis) — recurrent, sterile, migratory venous thromboses at unusual sites (subclavian, portal, jugular, superficial limb veins), driven by tumour mucins and tissue factor. Trousseau himself described the sign in himself and died of gastric cancer; it is most strongly associated with pancreatic adenocarcinoma. Treatment is therapeutic low-molecular-weight heparin.^[1][2]
• Venous thromboembolism — PDAC carries one of the highest VTE risks of any malignancy (8-fold the general population); recurrent VTE despite anticoagulation should raise suspicion of occult PDAC.
• Depression — present in up to 50% of patients in the year preceding diagnosis; new-onset depression in a previously well older patient may be a subtle presenting feature. (Rigorous evidence for this is limited and the association is debated.)
• Subcutaneous fat necrosis and polyarthralgia — the Schmid triad of acinar cell carcinoma (rare; lipase hypersecretion).
• Acute pancreatitis — pancreatic duct obstruction by a small tumour may present as acute pancreatitis; in an older patient with no gallstones or alcohol history, this is an indication for follow-up imaging to exclude a mass.

Atypical presentations^[1]

Examiners reward the candidate who recognises the presentations that are easy to miss:^[1][2]

• Acute pancreatitis as the first manifestation — ductal obstruction by a small tumour triggers a first episode of pancreatitis in an older patient with no traditional risk factors. Investigate the pancreas 4 to 6 weeks after resolution.
• Upper GI bleed from duodenal invasion or from isolated gastric varices (splenic-vein thrombosis from a tail tumour) — think tail of pancreas in a patient with variceal bleeding and a normal liver.
• Virchow's node (left supraclavicular lymphadenopathy, Troisier sign) — a metastasis from below the diaphragm; classically associated with gastric cancer but seen in advanced PDAC.
• Sister Mary Joseph nodule (periumbilical metastasis) — Sister Mary Joseph Dempsey, the surgical assistant who first noted it.
• Malignant ascites and Sister Mary Joseph nodule — peritoneal carcinomatosis.
• Migratory thrombophlebitis in an apparently well patient — occult PDAC; image the pancreas.
• Melaena or anaemia from occult duodenal invasion — rare first presentation.^[2]

Differential Diagnosis^[1]

The differential of obstructive jaundice is broad, and the examiner will test the candidate's ability to discriminate pancreatic cancer from its look-alikes. The key is to combine the clinical picture with the first-line imaging:^[2][1]

The two commonest exam traps are (a) mistaking ampullary carcinoma for pancreatic head cancer (it presents identically, but prognosis is much better and the operation may be the same) and (b) missing autoimmune pancreatitis in a patient labelled as having inoperable pancreatic cancer (AIP responds to steroids; a missed diagnosis costs the patient a Whipple and a correct diagnosis saves them from one).^[1][2]

Clinical & Bedside Assessment^[1]

A focused clinical assessment in a patient with suspected pancreatic cancer is rapid and methodical. The history is taken in the context of a patient who is often cachectic, deeply jaundiced, and frightened.^[2][1]

General examination^[1]

• Nutritional state — temporal wasting, sarcopenia, loss of subcutaneous fat, BMI. Cachexia is a poor prognostic feature independent of stage.
• Jaundice — scleral icterus, cutaneous icterus. Note the depth and distribution.
• Scratch marks — from pruritus.
• Skin — look for Peutz-Jeghers pigmentation (buccal mucosa, lips, fingers — autosomal dominant inheritance of STK11); FAMMM atypical naevi (large, irregular, multiple); jaundice; excoriations.
• Lymphadenopathy — left supraclavicular (Virchow's/Troisier sign), periumbilical (Sister Mary Joseph nodule), cervical, axillary.
• Thrombophlebitis — palpable cord-like superficial veins; check unusual sites (upper arm, chest, neck) for migratory Trousseau thromboses.
• Signs of chronic liver disease or chronic pancreatitis — spider naevi, palmar erythema, Dupuytren's contracture, parotid enlargement (alcoholic), abdominal surgical scars.^[2]

Abdominal examination^[1]

• Inspection — distension (ascites), surgical scars, caput medusae, prominent superficial veins.
• Palpation — the key findings are:
  • Palpable, non-tender, distended gallbladder (Courvoisier's sign) — in the right upper quadrant, smooth, round, moving with respiration, non-tender. Pathognomonic for malignant biliary obstruction (pancreatic head cancer, cholangiocarcinoma, ampullary cancer).
  • Hepatomegaly — from metastases or biliary congestion. Hard, irregular, knobbly liver = metastatic disease.
  • Epigastric mass — large head tumour, body/tail tumour (late), or a metastatic deposit in the omentum.
  • Splenomegaly — tail tumour with splenic-vein thrombosis (look for dilated gastric varices in the LUQ).
  • Ascites — peritoneal carcinomatosis; malignant cells on ascitic tap.
• Percussion — shifting dullness for ascites; loss of liver dullness in perforation (not relevant here).
• Auscultation — silent abdomen in ileus (late disease); bruit over the epigastrium (rare, vascular encasement).^[1][2]

The Courvoisier law and sign^[1]

The examiner is guaranteed to ask about Courvoisier. The sign is the palpable, non-tender, distended gallbladder in a jaundiced patient; the law is the inference.^[2][1]

Courvoisier's law (Ludwig Courvoisier, 1890): in the presence of jaundice, a palpable gallbladder is unlikely to be due to gallstones. The reasoning is that gallstones cause chronic recurrent cholecystitis, with mural fibrosis and a contracted, non-distensible gallbladder that cannot enlarge. A palpable, smoothly distended gallbladder implies a progressive, painless, low-grade obstruction that allows the gallbladder to distend gradually — and that pattern is the hallmark of malignant obstruction of the distal common bile duct (pancreatic head cancer, cholangiocarcinoma, ampullary carcinoma). The classic exception is Mirizzi syndrome (an impacted cystic-duct stone that compresses the common hepatic duct) and double-duct stones.^[1]

In real practice the gallbladder is palpable in only 20 to 30% of patients with head-of-pancreas cancer; the absence of the sign does not exclude cancer, but the presence of the sign is a near-pathognomonic bedside finding that should trigger urgent cross-sectional imaging.^[2]

Investigations^[1]

The workup of suspected pancreatic cancer is structured, multimodal, and time-critical. The goal of the first 48 to 72 hours is to (a) confirm the diagnosis, (b) stage the disease, and (c) assess fitness for surgery, chemotherapy, or palliation.^[1]

Blood tests^[1]

• Liver function tests (LFTs) — in biliary obstruction from a head tumour the picture is cholestatic: elevated bilirubin and alkaline phosphatase dominate, rather than a hepatitis pattern of predominant transaminase elevation.^[2]
• CA 19-9 (carbohydrate antigen 19-9) — the principal tumour marker in PDAC, used for monitoring response and detecting recurrence. It is not a screening or diagnostic test — effective screening is not available for PDAC, and benign biliary obstruction can also elevate levels, so interpret alongside imaging and tissue diagnosis.^[1][2]
• CEA (carcinoembryonic antigen) — may be elevated; a complementary marker only.
• Glucose and HbA1c — to identify new-onset diabetes and to characterise pre-existing diabetes for perioperative management.
• Coagulation (PT/INR, aPTT) — prolonged INR from vitamin K malabsorption in obstructive jaundice (bile is needed to absorb fat-soluble vitamins); correct before any procedure.
• Renal function, electrolytes, full blood count, group and save — baseline; needed for chemotherapy dosing.
• Nutritional markers — albumin; hypoalbuminaemia is a poor prognostic factor.
• Hepatic and renal function — for chemotherapy dosing and surgical fitness.

Imaging^[1]

• Contrast-enhanced CT (pancreatic protocol) — the mainstay of diagnosis and staging. A multiphase protocol images the pancreas during arterial and portal-venous enhancement: PDAC is characteristically hypoenhancing against normally enhancing parenchyma, and the surrounding vasculature (superior mesenteric artery and vein, coeliac axis, portal vein) is assessed to define resectability by the degree of arterial and venous involvement.^[1][5]
• Endoscopic ultrasound (EUS) with fine-needle aspiration (FNA) — EUS and EUS-guided FNA offer high diagnostic ability in pancreatic cancer and are the preferred route to tissue diagnosis before non-surgical therapy; EUS also assesses local vascular invasion and small lesions.^[5]
• Magnetic resonance cholangiopancreatography (MRCP) — non-invasive mapping of the biliary tree and pancreatic duct; a problem-solving tool for indeterminate lesions and duct anatomy.^[5]
• ERCP (endoscopic retrograde cholangiopancreatography) — primarily therapeutic in pancreatic cancer: biliary stenting to relieve jaundice before surgery or as palliation. Diagnostic ERCP has largely been replaced by CT/MRCP/EUS.^[2][5]
• 18F-FDG PET-CT — selected cases (occult metastasis, restaging after neoadjuvant therapy); not routine in resectable disease.^[5]
• Staging laparoscopy — performed before planned Whipple in many centres to detect occult peritoneal or liver metastases missed on CT and avoid non-therapeutic laparotomy.^[1][5]

Histology and molecular testing^[1]

• Core biopsy is required before any non-surgical therapy (neoadjuvant or palliative chemotherapy). Cytology from FNA is acceptable in the metastatic setting.
• Immunohistochemistry confirms ductal origin (CK7, CK19, CA 19-9) and excludes other primaries (CDX2 for intestinal, TTF-1 for lung, GATA3 for breast).
• Next-generation sequencing (NGS) on the biopsy identifies actionable mutations: KRAS (90%+), TP53, CDKN2A, SMAD4, BRCA1/2, PALB2, ATM, mismatch-repair status (MMR/MSI), NTRK, BRAF. Germline testing (blood) for BRCA1/2, PALB2, ATM, and the Lynch genes is now recommended for all patients with pancreatic cancer by NCCN (2020 onward) because of the implications for relatives and for PARP-inhibitor therapy. MSI-H/dMMR testing is mandatory because of the option of pembrolizumab.^[1][3]
• CA 19-9 baseline for monitoring, drawn after biliary decompression (stenting) if performed.

Management — Resuscitation^[1]

Pancreatic cancer rarely presents as a surgical emergency. The acute presentations are:^[1]

• Biliary obstruction with cholangitis (fever, jaundice, RUQ pain) — resuscitation with IV fluids, broad-spectrum IV antibiotics, and urgent biliary drainage (ERCP with biliary stenting); percutaneous transhepatic biliary drainage (PTBD) if ERCP fails or is unavailable. Definitive surgery or oncology referral follows.^[1][2]
• Coagulopathy from obstructive jaundice — vitamin K supplementation (fat-soluble vitamin malabsorption); FFP only for active bleeding or imminent surgery. Correct before any procedure.^[1]
• Gastric outlet obstruction (duodenal invasion) — NG decompression, IV fluids and electrolytes, PPI. Definitive treatment is palliative gastrojejunostomy or endoscopic duodenal stenting.^[1]
• Venous thromboembolism / Trousseau syndrome — therapeutic anticoagulation; hospitalised PDAC patients should receive VTE prophylaxis unless bleeding.^[1]
• Severe pain — WHO analgesic ladder; coeliac plexus block or neurolysis (EUS- or CT-guided) for refractory pain.^[1]
• Malnutrition and exocrine insufficiency — pancreatic enzyme replacement therapy (PERT) with meals, dietitian referral, and nutritional support.^[1]
• New-onset diabetes — endocrine input; insulin or oral agents as clinically appropriate.^[1]

Management — Definitive & Stepwise^[1]

Treatment is driven by resectability status, performance status (ECOG/Karnofsky), and patient preference. The MDT (medical oncology, surgical oncology, radiation oncology, hepatobiliary radiology, pathology, palliative care) makes the call.^[1]

Resectable disease (15 to 20% of patients)^[1]

Pancreatoduodenectomy (Whipple procedure) is the operation for tumours of the head of the pancreas, distal CBD, ampulla, and duodenum. It is one of the largest general surgical operations and should be performed at high-volume centres (mortality <3% vs >10% at low-volume centres).^[1][5]

Resection:^[1]

1. Head of pancreas — divided at the level of the portal vein (over the SMV).
2. Duodenum — second, third, and sometimes fourth parts.
3. Distal bile duct — divided above the cystic duct; the gallbladder is removed en bloc.
4. Distal stomach — classically (Whipple, 1935); the pylorus-preserving modification (Traverso-Longmire) preserves the entire stomach and the first part of the duodenum, with comparable oncological outcomes and better nutritional recovery. Pylorus-preserving is now the default at most centres.
5. Regional lymphadenectomy — standard lymphadenectomy includes stations 5, 6, 8a, 12b1, 12b2, 12c, 13a, 13b, 14p, 14d (Japanese classification); an extended template to stations 9 and 16 has not shown survival benefit in the European EXTROP trial.
6. Vascular resection — segmental resection of the SMV/PV with primary anastomosis or interposition graft (internal jugular, PTFE) is now standard for venous involvement without arterial encasement, with similar R0 and survival outcomes to standard resection in experienced hands. Arterial resection (SMA, coeliac) remains controversial; most centres reserve it for highly selected fit patients in a trial setting.^[1]

Reconstruction (three anastomoses, in order):^[1][2]

1. Pancreaticojejunostomy — the pancreatic remnant is anastomosed end-to-side to the jejunum. The most prone to leak; the source of postoperative pancreatic fistula (POPF). Variations: duct-to-mucosa, dunking, invagination. The prophylactic octreotide, internal pancreatic stent, and patch coverage of the jejunal staple line are all used to reduce leak rates.
2. Hepaticojejunostomy — end-to-side anastomosis of the proximal bile duct to the jejunum, downstream of the pancreatic anastomosis.
3. Gastrojejunostomy (or duodenojejunostomy in pylorus-preserving Whipple) — restores gastrointestinal continuity; placed distal to the other anastomoses.^[1]

Distal pancreatectomy ± splenectomy is the operation for body and tail tumours. Often performed laparoscopically or robotically. The splenic artery and vein run in close proximity to the pancreatic body/tail and are typically sacrificed, so splenectomy is routine; spleen-preserving distal pancreatectomy (Warshaw technique) is possible in selected benign or low-grade lesions. The pancreatic remnant is closed (stapler, hand-sewn, or patch) — there is no anastomosis. Spleen loss mandates vaccination against encapsulated organisms (meningococcus, pneumococcus, H. influenzae type b) at least 2 weeks preoperatively or 2 weeks postoperatively.^[1][5]

Total pancreatectomy removes the entire gland, spleen, gallbladder, and the duodenum, with a single Roux-en-Y reconstruction. Indicated for multifocal disease (main-duct IPMN with high-grade dysplasia), for positive neck margin on frozen section, and for hereditary pancreatitis with extensive neoplasia. Resulting insulin-dependent diabetes is brittle (loss of both alpha and beta cells, no glucagon response to hypoglycaemia).^[5]

Post-operative morbidity and mortality. Whipple has a 30 to 40% overall complication rate, but a 1 to 3% mortality rate in high-volume centres. Major complications:^[1][2][5]

• Postoperative pancreatic fistula (POPF) — 10 to 20%; the most feared; defined by the International Study Group on Pancreatic Surgery (ISGPS) as drain amylase >3× serum on or after POD 3. Grades B and C are clinically significant. Management: percutaneous drainage, octreotide, antibiotics, nutritional support (enteral or TPN), and rarely completion pancreatectomy. Grade C leaks carry up to 30% mortality.
• Delayed gastric emptying (DGE) — 10 to 30%; the most common; prolonged NG drainage and inability to tolerate oral intake beyond POD 7 to 14. Management: prokinetics (erythromycin, metoclopramide), patience, nutritional support.
• Post-pancreatectomy haemorrhage (PPH) — early (within 24 hours, surgical) or late (after POD 5 to 14, pseudoaneurysm). A sentinel bleed (a small, self-limiting haematemesis or drain bleed) before massive haemorrhage is the classic warning of a pseudoaneurysm from a POPF eroding the gastroduodenal artery stump. Urgent mesenteric angiography and coil embolisation is the treatment of choice; mortality of untreated rupture exceeds 50%.
• Anastomotic leak (hepaticojejunostomy or gastrojejunostomy) — uncommon (<5%); reoperation or percutaneous drainage.
• Intra-abdominal abscess — usually secondary to POPF; percutaneous drainage.
• Wound infection, pneumonia, DVT/PE, urinary tract infection — generic post-op complications.
• Pancreatic exocrine insufficiency — common after Whipple (>50%); PERT is lifelong.
• New-onset diabetes — after Whipple (10 to 25%) or total pancreatectomy (100%).^[1]

Adjuvant chemotherapy after resection begins within 4 to 8 weeks of surgery, ideally as soon as the patient is recovered. The current standard of care for fit patients is modified FOLFIRINOX (mFOLFIRINOX) for 12 cycles (about 6 months), as established by the PRODIGE 24/ACCORD 24 trial (Conroy 2018): median OS 54.4 months vs 35.0 months with gemcitabine alone (HR 0.64, p<0.001). For patients not fit for FOLFIRINOX, gemcitabine plus capecitabine (ESPAC-4) is the alternative (median OS 28.0 months vs 25.5 months with gemcitabine alone). Single-agent gemcitabine is reserved for those who cannot tolerate either combination. Adjuvant chemoradiotherapy is no longer routine after ESPAC-1 showed no benefit over chemotherapy alone; reserved for R1 margins in some centres.^[1][9][10]

Borderline resectable disease^[1]

Borderline resectable PDAC is now treated with neoadjuvant chemotherapy first in nearly all major centres. The intent is to (a) downstage the tumour to a resectable state, (b) treat occult micrometastatic disease early, and (c) identify patients with aggressive biology (who progress on chemotherapy and are spared a non-therapeutic operation).^[1][5][12]

Regimens:^[5][12]

• FOLFIRINOX (mFOLFIRINOX) for 4 to 6 months (8 cycles) is the preferred regimen for fit patients. R0 resection rate in contemporary series is 60 to 85%.
• Gemcitabine + nab-paclitaxel for 4 to 6 months is the alternative for patients not fit for FOLFIRINOX.^[5]

After neoadjuvant therapy, restaging with pancreatic-protocol CT and CA 19-9 is performed. If the tumour has responded (CA 19-9 down, no progression) and the patient remains operable, proceed to pancreatoduodenectomy (with vascular resection/reconstruction as needed). If progression, convert to palliative chemotherapy. The PREOPANC trial (Dutch, 2018) showed neoadjuvant gemcitabine-based chemoradiotherapy improved R0 and median OS vs upfront surgery in (borderline) resectable PDAC. The Murphy 2019 trial of total neoadjuvant FOLFIRINOX + losartan + chemoradiotherapy achieved a 61% resection rate in locally advanced PDAC, with a 33-month median OS in resected patients — the strongest evidence for total neoadjuvant therapy.^[12][5]

Locally advanced unresectable disease^[1]

Defined as >180° encasement of SMA or coeliac axis, or non-reconstructible SMV/PV occlusion, with no distant metastases. Treatment is induction chemotherapy (FOLFIRINOX or gemcitabine/nab-paclitaxel) for 4 to 6 months, then restaging. If response — particularly if the tumour drops below 180° SMA contact — consider surgical exploration in high-volume centres. If stable disease, consider consolidation chemoradiotherapy (capecitabine-based 50.4 to 54 Gy in 28 to 30 fractions, or SBRT in selected centres) for local control. If progression, convert to second-line chemotherapy. Median OS 15 to 20 months.^[1][5]

Metastatic disease (50% of patients)^[1]

The goal is palliation and life extension. For patients with good performance status (ECOG 0 to 1), the standard first-line is FOLFIRINOX (PRODIGE 4/ACCORD 11, Conroy 2011): oxaliplatin 85 mg/m², leucovorin 400 mg/m², irinotecan 180 mg/m², and fluorouracil 400 mg/m² bolus followed by 2,400 mg/m² over 46 hours, every 2 weeks. Median OS 11.1 months vs 6.8 months with gemcitabine (HR 0.57); median PFS 6.4 vs 3.3 months, objective response rate 31.6% vs 9.4%. FOLFIRINOX caused more adverse events, including febrile neutropenia in 5.4% of patients. Gemcitabine + nab-paclitaxel (MPACT, Von Hoff 2013) is the alternative first-line: nab-paclitaxel 125 mg/m² followed by gemcitabine 1,000 mg/m² on days 1, 8, and 15 every 4 weeks, given until disease progression; median OS 8.5 vs 6.7 months (HR 0.72), 1-year survival 35% vs 22%, with increased peripheral neuropathy and myelosuppression. In MPACT, gemcitabine monotherapy was 1,000 mg/m² weekly for 7 of 8 weeks then days 1, 8, 15 of each 4-week cycle.^[7][8][1]

Second-line options after progression on first-line: nanoliposomal irinotecan + 5-FU/leucovorin (NAPOLI-1, Wang-Gillam 2016) improved median OS 6.2 vs 4.2 months; FOLFOX is widely used off-trial. Pembrolizumab is reserved for the rare MSI-H/dMMR tumour (<1% of PDAC; KEYNOTE-158).^[1]

Maintenance therapy for germline BRCA1/2-mutated patients whose metastatic disease has not progressed on first-line platinum-based chemotherapy: olaparib tablets 300 mg twice daily (POLO trial, Golan 2019). Olaparib improved median PFS from 3.8 to 7.4 months (HR 0.53); an interim analysis of overall survival showed no difference (median 18.9 vs 18.1 months, HR 0.91).^[11]

Palliative care runs in parallel: pain control (coeliac plexus block for back pain, WHO analgesic ladder), biliary decompression (covered metal stent, SEMS), duodenal stenting for gastric outlet obstruction, PERT for exocrine insufficiency, antiemetics, psychological support, early referral to specialist palliative care (improves both quality of life and survival, per Temel 2010 in lung cancer, replicated in pancreatic).^[1]

Enlarge

Staging & Systemic Therapy — Doses, Trials, and NCCN Criteria^[1]

AJCC TNM 8th edition^[1]

The AJCC 8th edition (Amin 2017) is the current staging system. Resectability is a separate clinical-radiological assessment, not a T-stage.^[4]

Resectability criteria (NCCN/AHPBA/SSO consensus)^[1]

• Resectable:
  • No distant metastases.
  • No radiographic evidence of SMA or coeliac axis abutment or encasement.
  • No radiographic evidence of SMV/PV distortion (clear fat plane around these vessels).
  • ≤180° contact with SMV/PV without vein deformity.
• Borderline resectable (BR-PC):
  • SMV/PV: >180° contact, or ≤180° contact with vein deformity, or short-segment occlusion with reconstructible vessel above and below.
  • SMA / coeliac axis: ≤180° contact of the circumference.
  • No distant metastases.
• Locally advanced (unresectable):
  • SMA / coeliac axis: >180° encasement.
  • SMV/PV: non-reconstructible occlusion.
  • No distant metastases.^[1]

Landmark trials at a glance^[1]

• PRODIGE 4/ACCORD 11 (Conroy 2011, NEJM) — FOLFIRINOX vs gemcitabine in metastatic PDAC, 342 patients, ECOG 0 to 1. Median OS 11.1 vs 6.8 months (HR 0.57), median PFS 6.4 vs 3.3 months, ORR 32% vs 9%. Established FOLFIRINOX as first-line for fit patients.^[7]
• MPACT (Von Hoff 2013, NEJM) — gemcitabine + nab-paclitaxel vs gemcitabine in metastatic PDAC, 861 patients. Median OS 8.5 vs 6.7 months (HR 0.72), median PFS 5.5 vs 3.7 months, ORR 23% vs 7%. Established the doublet as first-line for patients not suitable for FOLFIRINOX.^[8]
• ESPAC-4 (Neoptolemos 2017, Lancet) — adjuvant gemcitabine + capecitabine vs gemcitabine alone after R0/R1 resection, 732 patients. Median OS 28.0 vs 25.5 months (HR 0.82, p=0.05). Established the doublet as adjuvant option.^[10]
• PRODIGE 24/ACCORD 24 (Conroy 2018, NEJM) — adjuvant mFOLFIRINOX vs gemcitabine after R0/R1 resection, 493 patients, ECOG 0 to 1. Median OS 54.4 vs 35.0 months (HR 0.64), median DFS 21.6 vs 12.8 months, 3-year DFS 39.7% vs 21.4%. The largest survival gain in adjuvant PDAC ever, and the new standard of care in fit patients.^[9]
• POLO (Golan 2019, NEJM) — maintenance olaparib vs placebo in germline BRCA-mutated metastatic PDAC with no progression on ≥16 weeks of platinum-based chemotherapy, 154 patients. Median PFS 7.4 vs 3.8 months (HR 0.53). First precision-medicine indication in PDAC.^[11]
• Murphy total neoadjuvant (2019, JAMA Oncol) — total neoadjuvant FOLFIRINOX + losartan + chemoradiotherapy in locally advanced PDAC. R0 resection rate 61%, median OS in resected patients 33 months. Strongest evidence for total neoadjuvant therapy.^[12]
• PREOPANC (2018, J Clin Oncol) — neoadjuvant gemcitabine-based chemoradiotherapy vs upfront surgery in (borderline) resectable PDAC. R0 rate 71% vs 40%, median OS 17.1 vs 13.5 months (HR 0.74). The Dutch randomised trial that underpins the neoadjuvant paradigm in BR-PC.^[5]
• ESPAC-1 (Neoptolemos 2004, JAMA) — adjuvant chemotherapy (5-FU/leucovorin) vs chemoradiotherapy vs surgery alone. Chemotherapy improved 5-year OS vs no chemo; chemoradiotherapy added no benefit and may have harmed. Established the modern adjuvant chemotherapy paradigm.^[5]
• Waddell 2015 (Nature) — ICGC whole-genome sequencing of 100 PDACs; four genomic subtypes: stable, locally rearranged (BRCA/PALB2 enriched), scattered, and unstable. Foundation for precision-medicine approach.^[5]

Specific Subtypes & Scenarios^[1]

Periampullary carcinoma^[1]

As noted, the umbrella term for tumours of the ampulla of Vater, distal CBD, or second part of the duodenum. Present identically to pancreatic head cancer (painless jaundice) but with a much better prognosis — 5-year survival 40 to 50% after Whipple (intestinal-type ampullary adenocarcinoma 50 to 70%; distal cholangiocarcinoma 30 to 40%; duodenal 40 to 50%). Treatment: pancreatoduodenectomy with regional lymphadenectomy, and adjuvant chemotherapy is debated (CAPOX or gemcitabine-based regimens). The differential is settled on histopathology and immunohistochemistry (CK7/CK20/CDX2 patterns).^[2]

IPMN (intraductal papillary mucinous neoplasm)^[1]

A mucin-producing cystic tumour of the pancreatic duct with potential for malignant transformation. Subtypes:^[2]

• Main-duct IPMN — segmental or diffuse dilation of the main pancreatic duct >5 mm without another cause. Malignancy rate 40 to 70%; resect.
• Branch-duct IPMN — cystic dilation of side branches. Malignancy rate 5 to 15%. Resect if high-risk stigmata (obstructive jaundice, enhancing solid component, main pancreatic duct ≥10 mm) or worrisome features (pancreatitis, cyst ≥3 cm, thickened enhancing cyst walls, non-enhancing mural nodule <5 mm, main pancreatic duct 5 to 9 mm, abrupt change in MPD calibre with distal pancreatic atrophy) — the Fukuoka/Kyoto criteria.^[2][5]

Surveillance of unresected IPMN: MRI/MRCP or CT every 1 to 2 years.^[2]

Pancreatic neuroendocrine tumour (pNET)^[1]

pNETs are a distinct group of rarer pancreatic neoplasms, separate from PDAC. Functional tumours produce hormone-excess syndromes — insulinoma (fasting hypoglycaemia), gastrinoma (Zollinger-Ellison syndrome), glucagonoma, VIPoma, and somatostatinoma — while most are non-functional and present late or incidentally. Surgical resection is the mainstay for localised disease; somatostatin analogues and other targeted agents are used in advanced disease. Management is specialised and beyond the scope of this PDAC topic.^[2]

Acinar cell carcinoma^[1]

A rare, aggressive variant presenting with the Schmid triad of subcutaneous fat necrosis, polyarthralgia, and eosinophilia from lipase hypersecretion. Resection when localised; gemcitabine-based chemotherapy for metastatic disease.^[2]

Autoimmune pancreatitis (IgG4-related)^[1]

Type 1 autoimmune pancreatitis is part of the IgG4-related disease spectrum and is the classic exam trap: it can mimic PDAC radiologically and clinically — including obstructive jaundice — but is steroid-responsive. Exclude it before committing to a Whipple.^[2]

Hereditary pancreatic cancer^[1]

The high-risk surveillance clinic is now a standard offering. Candidates for surveillance include: (a) carriers of germline mutations with high PDAC penetrance (BRCA2, PALB2, ATM, STK11, CDKN2A, PRSS1, MLH1/MSH2/MSH6), (b) individuals with ≥2 first-degree relatives with PDAC ("familial PDAC"), and (c) those with hereditary pancreatitis.^[3][14]

• Surveillance modality: annual MRI/MRCP (and/or EUS) starting at age 50 (or 40 for STK11 carriers, 35 for PRSS1), or 10 years before the youngest affected relative's age at diagnosis. The CAPS (Cancer of the Pancreas Screening) consortium studies show surveillance detects PDAC at stage I in over 80% of cases, vs <20% in symptomatic presentation. CT adds radiation burden and is reserved for EUS/MRI abnormalities.^[14]
• Germline testing is now recommended for all patients with pancreatic cancer (NCCN 2020), not just those with a family history, because of the implications for relatives and for PARP-inhibitor therapy.
• Screening in chronic pancreatitis (non-hereditary) is debated; CA 19-9 and annual CT or MRI are used in some centres.

Pancreatic cancer in pregnancy^[1]

Exceedingly rare (1 in 1,000,000 pregnancies). The challenge is that abdominal pain, nausea, and weight loss are common in pregnancy and may delay diagnosis. MRI without gadolinium is the imaging of choice. Surgery is ideally deferred to the second trimester (or postpartum) if curative, and chemotherapy (FOLFIRINOX or gemcitabine) is contraindicated in the first trimester. Most cases are diagnosed at an advanced stage.^[2]

Complications & Pitfalls^[1]

Of the disease^[1]

• Obstructive jaundice — pruritus, malabsorption (steatorrhoea from lack of bile), coagulopathy (vitamin K deficiency), cholangitis (Charcot triad).
• Duodenal obstruction — vomiting, dehydration, malnutrition.
• Intractable pain — from coeliac/superior mesenteric plexus invasion; the dominant symptom of body/tail tumours and advanced disease.
• Venous thromboembolism / Trousseau syndrome — paraneoplastic hypercoagulability; high VTE risk (8× general population).
• Malnutrition and cachexia — exocrine insufficiency (steatorrhoea, weight loss), anorexia, catabolic state; PERT and dietitian support are under-utilised.
• Diabetes — from tumour destruction of islets and from paraneoplastic insulin resistance.
• Hepatic and peritoneal metastases — the commonest end-state.^[1]

Of the Whipple procedure^[1]

• Pancreatic fistula (POPF) — a leak from the pancreaticojejunostomy and the most feared complication. Management: percutaneous drainage of collections, antibiotics if infected, nutritional support, and reoperation (including completion pancreatectomy) only as a last resort.^[1][2]
• Delayed gastric emptying — prolonged NG drainage and intolerance of oral intake; managed with prokinetics, NG decompression, and patience.^[1][2]
• Post-pancreatectomy haemorrhage (PPH) — may be early (anastomotic) or late (erosion of a visceral artery, often after a fistula). A small sentinel bleed can precede massive haemorrhage and demands urgent angiography with embolisation; surgery only if unstable.^[1]
• Anastomotic leak (hepaticojejunostomy, gastrojejunostomy) — reoperation or percutaneous drainage.
• Intra-abdominal abscess — usually secondary to POPF; percutaneous drainage.
• Wound infection, pneumonia, DVT/PE — generic post-operative complications.
• Pancreatic exocrine insufficiency — common after Whipple; lifelong PERT.^[1]
• New-onset diabetes — may follow pancreatic resection; insulin-dependent after total pancreatectomy.^[1]

Classic pitfalls^[1]

• Missing Courvoisier's sign — a palpable non-tender gallbladder in a jaundiced patient is cancer until proven otherwise.
• Mistaking painless jaundice for gallstones without imaging — gallstones are by far the commonest cause of jaundice in a 70-year-old, but painless progressive jaundice is malignant until proven otherwise.
• Not doing staging laparoscopy before Whipple — occult peritoneal disease is missed in 10 to 20%.
• Not offering FOLFIRINOX to fit patients with metastatic disease — depriving them of 4 to 6 months additional survival.
• Not relieving jaundice before surgery — stent first to normalise bilirubin and coagulation.
• Not considering pancreatic cancer in new-onset diabetes in an older, thin patient with weight loss.
• Treating autoimmune pancreatitis (AIP) as inoperable cancer — a steroid trial is diagnostic and may avoid Whipple.
• Confusing ampullary carcinoma with pancreatic head cancer — they present identically but have a markedly different prognosis; histology is the only way to distinguish.
• Missing sentinel bleed after Whipple — dismiss at your peril; urgent angiography.
• Not testing BRCA in patients with PDAC — denies them and their relatives the benefits of germline testing and PARP inhibitors.
• Forgetting to vaccinate before or after splenectomy (pneumococcus, meningococcus, Hib).
• Ignoring Lewis-negative CA 19-9 — normal CA 19-9 in 5 to 10% of the population is uninformative, not reassuring.^[1]

Prognosis & Disposition^[1]

Pancreatic cancer has the worst overall prognosis of any major solid malignancy, with an overall 5-year survival of approximately 10% in most series (12% in the most recent SEER data, 2023). The principal reason is that over 80% of patients present at an unresectable stage.^[1][2][5]

• Overall 5-year survival: under 10% (the main reason: over 80% present at an unresectable stage).
• After curative R0 resection + adjuvant mFOLFIRINOX: median OS 54 months, 5-year survival 30 to 40% (improving with PRODIGE-24 era).^[9]
• After R0 + gemcitabine/capecitabine: 5-year 25 to 30%.^[10]
• After R0 + gemcitabine alone: 5-year 20 to 25%.^[1]
• Locally advanced, unresectable: median OS 15 to 20 months with chemotherapy ± chemoradiotherapy.^[5]
• Metastatic, treated with FOLFIRINOX: median OS 11 months, 5-year 3%.^[7]
• Metastatic, treated with gemcitabine/nab-paclitaxel: median OS 8.5 months.^[8]
• Metastatic, best supportive care: median OS 3 to 6 months.^[1]

Adverse prognostic factors (multivariate analyses):^[1]

• Advanced stage at presentation (most patients present with locally advanced or metastatic disease).^[1]
• Positive resection margin (R1/R2).
• Lymph node involvement.
• Elevated CA 19-9 (pre-treatment elevation is adverse; normalisation with treatment is favourable).
• Large tumour size; perineural, lymphovascular, or venous invasion.
• Poor performance status and weight loss.
• New-onset diabetes.^[1]

Follow-up after resection is variable across guidelines but generally includes clinical review, CA 19-9, and CT every 3 to 6 months for the first 2 years, then every 6 months. Recurrence is common (over 70% within 2 years), most often in the liver, peritoneum, or locally at the surgical bed.^[1]

Disposition: patients with resected disease are followed in surgical oncology; unresectable or metastatic patients need parallel oncology and palliative care input from the first encounter (early palliative care improves outcomes, per Temel 2010 and replicated in PDAC cohorts).^[1]

Special Populations^[1]

Hereditary risk (BRCA2, Peutz-Jeghers, Lynch, hereditary pancreatitis)^[1]

• Germline testing is now recommended for all patients with pancreatic cancer (NCCN 2020 onward), regardless of family history, because (a) BRCA1/2/PALB2/ATM are found in 4 to 10% of unselected PDAC, (b) results inform PARP-inhibitor use, and (c) results affect first-degree relatives.^[3][14]
• Surveillance for high-risk carriers: annual MRI/MRCP ± EUS from age 50 (40 for STK11, 35 for PRSS1), or 10 years before the youngest affected relative. Biannual surveillance is increasingly considered; CAPS data show 12-monthly detects 80% of stage I disease.^[14]
• Therapeutic implications: olaparib for germline BRCA1/2-mutated metastatic PDAC after platinum response; platinum-based chemotherapy is preferred first-line in BRCA-mutated disease (the SWOG S1505 and POLO subset data both support); immune checkpoint inhibitors for MSI-H/Lynch.

New-onset diabetes in an older, thin patient with weight loss^[1]

A clinical pearl that has moved from anecdote to evidence: new-onset diabetes in a patient over 50 with weight loss has approximately a 1% probability of underlying PDAC and warrants cross-sectional imaging (pancreatic-protocol CT or MRI). Studies using the ratio of CA 19-9 to age, or a combined risk model (the ENDPAC score: weight loss, smoking, age at diabetes onset), identify a sub-group with 4 to 5% PDAC prevalence — well above the threshold for further investigation. Resection in such patients often yields early-stage disease.^[1][3]

Elderly and frail^[1]

• Surgery is feasible in selected elderly patients; the decision should weigh physiological age, performance status, comorbidity, and patient preference, not chronological age alone.^[1]
• Chemotherapy: regimens and doses must be individualised; multi-agent regimens such as FOLFIRINOX are reserved for fit patients with good performance status and adequate organ function.^[1][7]
• Best supportive care is appropriate for patients with poor performance status, integrated alongside oncology input.^[1]

Anticoagulated^[1]

• Warfarin is often switched to LMWH during chemotherapy because of drug interactions (capecitabine, 5-FU) and INR instability.
• Direct oral anticoagulants (DOACs) are used cautiously; rivaroxaban and apixaban are reasonable, but interactions with enzyme inhibitors (e.g. azoles) and vomiting/diarrhoea limit use.
• Therapeutic anticoagulation is required for Trousseau syndrome; LMWH is the standard.^[1]

Pregnant^[1]

PDAC in pregnancy is exceptionally rare. MRI without gadolinium is the imaging of choice. Surgery is ideally deferred to the second trimester (or postpartum) if curative; chemotherapy is contraindicated in the first trimester. Most cases are diagnosed at an advanced stage, and prognosis is poor.^[1]

Renal or hepatic impairment^[1]

• Chemotherapy dosing requires individualisation in hepatic and renal impairment; combination regimens such as FOLFIRINOX were trialled in patients with good performance status (ECOG 0-1) and adequate organ function, and are avoided where organ function is significantly compromised.^[7][1]

Evidence, Guidelines & Regional Differences^[1]

NCCN (US, 2024)^[1]

NCCN is the most widely cited guideline for PDAC. The 2024 update positions:^[1]

• Resectable: surgery first, then adjuvant mFOLFIRINOX for 12 cycles (fit) or gemcitabine/capecitabine (less fit).
• Borderline resectable: neoadjuvant FOLFIRINOX or gem/nab for 4 to 6 months, restage, then surgery if response.
• Locally advanced: induction FOLFIRINOX or gem/nab, then chemoradiotherapy if response; surgery in highly selected.
• Metastatic, fit: FOLFIRINOX first-line; alternative gem/nab; olaparib maintenance in germline BRCA after platinum; pembrolizumab in MSI-H.
• Palliative: biliary stenting, coeliac plexus block, PERT, early palliative care referral.
• Germline testing for all patients; somatic NGS on the tumour to identify actionable alterations.^[1]

ESMO (Europe, 2023 update)^[1]

ESMO broadly follows NCCN with minor differences: emphasises total neoadjuvant therapy in BR-PC, recommends FOLFIRINOX as first-line in fit metastatic patients, and is more conservative on SBRT for locally advanced disease.^[1]

NICE (UK, 2023)^[1]

NICE NG85 (pancreatic cancer in adults) recommends:^[1]

• Adjuvant mFOLFIRINOX as first option after resection in fit patients; gemcitabine + capecitabine for those who cannot tolerate FOLFIRINOX; single-agent gemcitabine for less fit.
• Neoadjuvant chemotherapy for borderline resectable disease (the All-Party Parliamentary Group on Pancreatic Cancer report of 2023 calls for universal access).
• FOLFIRINOX for fit metastatic patients.
• Routine germline testing is now offered through the NHS Genomic Medicine Service.
• EUS-FNA for tissue diagnosis before therapy.^[1]

ASCO guidelines^[1]

• Adjuvant mFOLFIRINOX for fit patients (strong recommendation).
• Germline testing for all PDAC patients.
• Routine assessment of sarcopenia and frailty in older patients before surgery.
• Early integration of palliative care.^[1]

ICMR (India)^[1]

The Indian Council of Medical Research guidelines (2023) recognise that:^[1]

• Tropical (nutritional) pancreatitis is a distinct, geographically-confined precursor in southern India (Kerala, Karnataka, Tamil Nadu, Andhra Pradesh); patients present in their 30s to 50s with diabetes, steatorrhoea, and large ductal calculi; lifetime PDAC risk is high.
• Cost and access limit the use of FOLFIRINOX; gemcitabine-based regimens remain the practical standard in much of public-sector practice, with capecitabine added when feasible.
• Late presentation and limited access to high-volume surgical centres are the dominant barriers; centralisation to high-volume centres is recommended.
• Pancreatic enzyme replacement therapy is under-utilised; PERT is recommended in all PDAC patients with weight loss or steatorrhoea.
• Pain control is a major quality-of-life issue; coeliac plexus block availability is patchy; oral morphine is the mainstay.^[1]

Japan / JSHP^[1]

Japanese surgeons take a more aggressive surgical approach: extended lymphadenectomy, arterial resection and reconstruction in selected patients, and aggressive neoadjuvant chemoradiotherapy. The JASPAC-01 trial (Uesaka 2016, JAMA) showed adjuvant S-1 (an oral fluoropyrimidine) superior to gemcitabine after resection in Japanese patients (2-year OS 70% vs 53%), but S-1 is not registered for use in Europe or the US, and the results have not been replicated in Western populations.^[1]

High-volume centres^[1]

Whipple procedure mortality is significantly lower in high-volume centres (under 3%) than in low-volume centres (over 10%). Centralisation of pancreatic surgery to centres performing at least 20 to 30 Whipples per year is recommended by all major guidelines. The patient should be referred to a hepatobiliary multidisciplinary team (MDT) at a high-volume centre for all resectable and borderline-resectable cases.^[1][5]

Key trials and what they changed^[1]

• Conroy 2011 (PRODIGE 4/ACCORD 11) — FOLFIRINOX in metastatic PDAC: 11.1 vs 6.8 months. Changed practice to FOLFIRINOX first-line in fit patients.^[7]
• Von Hoff 2013 (MPACT) — gemcitabine + nab-paclitaxel in metastatic PDAC: 8.5 vs 6.7 months. Established the doublet as an alternative first-line.^[8]
• Conroy 2018 (PRODIGE 24/ACCORD 24) — adjuvant mFOLFIRINOX: 54.4 vs 35.0 months. Changed practice to mFOLFIRINOX adjuvant for fit patients.^[9]
• Neoptolemos 2017 (ESPAC-4) — adjuvant gem-cap: 28.0 vs 25.5 months. Established the doublet adjuvant for less fit patients.^[10]
• Golan 2019 (POLO) — olaparib maintenance in germline BRCA: PFS 7.4 vs 3.8 months. First precision-medicine indication in PDAC.^[11]
• Murphy 2019 (JAMA Oncol) — total neoadjuvant FOLFIRINOX + losartan + CRT: 61% resection rate, 33-month median OS in resected patients. Best evidence for total neoadjuvant therapy.^[12]
• Uesaka 2016 (JASPAC-01) — adjuvant S-1 vs gemcitabine in Japanese: 2-year OS 70% vs 53%. S-1 standard in Japan; not generalisable to Western populations.

Exam Pearls^[1]

• Painless obstructive jaundice with weight loss in an older patient — image the pancreas; pancreatic head cancer until proven otherwise.^[2]
• Smoking is the biggest modifiable risk factor (75% increased risk in current smokers). Others: chronic pancreatitis, diabetes, obesity, family history.^[1][15]
• Four major driver genes: KRAS, CDKN2A, TP53, SMAD4. KRAS mutation and CDKN2A alterations are the early events.^[5]
• Only 10 to 15% are resectable at presentation. Whipple for head tumours. Distal pancreatectomy + splenectomy for body/tail.^[1]
• Whipple = pancreatoduodenectomy: remove head of pancreas, duodenum, distal CBD, gallbladder, sometimes distal stomach. Three anastomoses: pancreaticojejunostomy, hepaticojejunostomy, gastrojejunostomy.^[1]
• mFOLFIRINOX adjuvant after resection (PRODIGE 24, 54 vs 35 mo OS). FOLFIRINOX or gem/nab for metastatic.^[9][7][8]
• Whipple complications: pancreatic fistula (most feared, sentinel bleed), delayed gastric emptying, post-pancreatectomy haemorrhage.^[1]
• Five-year survival 2 to 9% — worst of all cancer sites. After resection + adjuvant mFOLFIRINOX: 3-year OS 63.4% (PRODIGE 24). Projected to become the 2nd-leading cause of cancer death by 2030.^[1][2][9]
• Most patients present with locally advanced (30-35%) or metastatic (50-55%) disease — this is why survival is poor.^[1]
• New-onset diabetes in older thin patient with weight loss → image the pancreas.^[1]
• Olaparib maintenance for germline BRCA1/2-mutated metastatic PDAC (POLO trial, 7.4 vs 3.8 mo PFS).^[11]
• CA 19-9 is for monitoring, not screening or diagnosis.^[1]
• Sentinel bleed after Whipple = pseudoaneurysm; urgent angiography and embolisation.^[1]
• Ampullary carcinoma has a much better prognosis than PDAC — do not lump them.^[2]
• Germline testing is now recommended for ALL patients with PDAC.^[3]
• Total neoadjuvant FOLFIRINOX + losartan + chemoradiotherapy in locally advanced PDAC: R0 resection rate 61%.^[12]
• Autoimmune pancreatitis is a steroid-responsive mimic — a missed diagnosis costs a Whipple.^[2]
• Centralise Whipple to high-volume centres.^[1]
• Vaccinate splenectomy patients against encapsulated organisms.^[5]
• Adjuvant gemcitabine + capecitabine (ESPAC-4): gemcitabine 1,000 mg/m² weekly for 3 of every 4 weeks + capecitabine 1,660 mg/m² orally daily for 21 of every 28 days, for 6 cycles.^[10]
• Gemcitabine + nab-paclitaxel: gem 1,000 mg/m² + nab 125 mg/m² days 1, 8, 15, every 4 weeks, until disease progression.^[8]
• FOLFIRINOX: oxaliplatin 85 + irinotecan 180 + leucovorin 400 + 5-FU bolus 400 + 5-FU 2,400 mg/m² over 46 h, every 14 days.^[7]
• Olaparib maintenance: 300 mg orally twice daily (tablets).^[11]

Exam application bank (NEET-PG / INICET)

One-line answer

Pancreatic carcinoma (ductal adenocarcinoma) is an aggressive malignancy with a 5-year survival under 10% — the worst of any solid organ cancer. Risk factors: smoking, chronic pancreatitis, diabetes, obesity, family history, BRCA2. Head of pancreas (70%): presents with painless obstructive jaundice, weight loss, Courvoisier's sign (palpable non-tender gallbladder). Body/tail: presents late with pain radiating to the back. Diagnosis: CT pancreas protocol + CA 19-9 + EUS-FNA biopsy. Only 15 to 20% are resectable at presentation (Whipple / pancreatoduodenectomy for head tumours). FOLFIRINOX or gemcitabine/nab-paclitaxel for metastatic. Jaundice relief by ERCP stenting. Almost uniformly fatal.

Worked stems (answer without another resource)

Stem 1 — Classic presentation. Map symptoms to mechanism; name the first investigation and first treatment step with dose/route if drug therapy is standard. ^[1]

Stem 2 — Unstable / complicated. List red flags that force immediate resuscitation, theatre, ICU, antidote, or reperfusion — and what you do in the first 15 minutes. ^[1]

Stem 3 — Atypical group. Elderly, pregnancy, child, or immunocompromised: how presentation and thresholds change. ^[1]

Stem 4 — Differential trap. Name the three closest mimics and one discriminator for each. ^[1]

Stem 5 — Disposition. Who goes home with safety-netting, who is admitted, who needs HDU/ICU/theatre, and what follow-up is mandatory. ^[1]

Rapid viva checklist

1. Definition + classification
2. Pathophysiology chain
3. Bedside signs / criteria
4. Score with exact components (if any)
5. Emergency bundle
6. Definitive therapy with doses
7. Complications of disease and of treatment
8. Special populations
9. Guideline/trial name if classic
10. Three exam traps

Coverage self-check

If you cannot answer any stem above from this page alone, re-read the matching section — the page is intended to be self-sufficient for final-prof and NEET-PG/INICET questions on Pancreatic Carcinoma.